Ribbon Biolabs names Jodi Barrientos as chief business officer
Austria-based DNA synthesis specialist Ribbon Biolabs has appointed Jodi Barrientos as chief business officer.
With over 17 years of experience in industry-leading life science and diagnostics companies, Ms Barrientos brings deep knowledge and expertise in commercial strategy, operations, and enterprise development focused on key synthetic biology and genomics markets. In her new role, she will be responsible for accelerating the company’s commercial efforts of synthesizing DNA molecules for clients in biopharma, biotech, and academia.
Prior to joining Ribbon Biolabs, Ms Barrientos was vice president of commercial marketing for the diagnostics genomics group at Agilent Technologies, where she leveraged her market knowledge and commercial experience to bring innovative products to the genomics, pathology, and companion diagnostics markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze